{"title":"Exon 20 Group","summary":"Free global group for people with EGFR or HER2 exon 20 insertion cancers: case navigation, biomarker report review, trial matching, peer buddies and support groups.","body":"The Exon 20 Group is a global community for people with EGFR exon 20 or HER2 exon 20 insertion mutations, in lung cancer and other solid tumors, and their families. It's home to the EGFR Exon 20 Warriors and HER2 Warriors support groups. It's a special initiative of ICAN, the International Cancer Advocacy Network, a 501(c)(3).\n\n## What they offer\n\n- Ongoing navigation of your case, including review of your biomarker testing reports.\n- Second opinion referrals and molecular tumor board access when doctors disagree.\n- Clinical trial, expanded access and compassionate use matching.\n- An \"Angel Buddy,\" a peer who helps with side effects and the day-to-day.\n- Closed online support groups, virtual meet-ups and webinars on new drugs.\n- Research it funds, a mutation registry, and surveys or studies that pay you for your time.\n\n## How to join and what it costs\n\nAs of October 2026, membership is free. They onboard each patient first: you fill out the New Patient Form on their website (or email or call), then have an intake call to confirm your mutation from your NGS report. They review consent forms with you on that call.\n\n## How it fits with other groups here\n\nThe Exon 20 Group is narrower than [EGFR Resisters](/companies/egfr-resisters/), which covers all EGFR lung cancer. Its sister ICAN group for MET is [MET Crusaders](/companies/met-crusaders/). Other biomarker groups here include [ALK Positive](/companies/alk-positive/), [The ROS1ders](/companies/the-ros1ders/) and [KRAS Kickers](/companies/kras-kickers/). My [find support](/resources/find-support/) guide covers how to choose.\n\n## Questions I would ask\n\n- What do I need to send for my intake call?\n- Can you review my NGS report and confirm my exact insertion?\n- Which trials or expanded access options fit me?\n- Can you pair me with an Angel Buddy?\n\n## Contacts\n\n- Website: [exon20group.org](https://www.exon20group.org/)\n- How to join: New Patient Form on the website\n- Email: exon20@exon20group.org\n- Phone: 602-618-0183","topics":["getting-started","expert-support","clinical-trials"],"capabilities":["patient-support","clinical-trials","research-support"],"organizationType":"nonprofit","services":["peer-support","patient-education","advocacy","trial-navigation","research-navigation"],"communityFocus":["EGFR exon 20 insertion","HER2 exon 20 insertion","EGFR-positive lung cancer","Caregivers"],"sources":[{"id":"home","label":"Exon 20 Group home page","url":"https://www.exon20group.org/","publisher":"Exon 20 Group","checkedAt":"2026-10-22","supports":"Free membership after onboarding; New Patient Form or call; navigation, report review, second opinions, trial/expanded access matching, Angel Buddy, support groups, research, compensated studies; special initiative of ICAN, 501(c)(3), EIN 86-0818253.","type":"official"},{"id":"horn","label":"Marcia K. Horn, JD (MET Crusaders)","url":"https://metcrusaders.org/team/marcia-k-horn-jd/","publisher":"MET Crusaders","checkedAt":"2026-10-22","supports":"Marcia Horn leads ICAN; the Exon 20 Group is under ICAN's umbrella.","type":"official"},{"id":"propublica","label":"International Cancer Advocacy Network nonprofit record","url":"https://projects.propublica.org/nonprofits/organizations/860818253","publisher":"ProPublica Nonprofit Explorer","checkedAt":"2026-10-22","supports":"International Cancer Advocacy Network, Phoenix AZ, EIN 86-0818253, 501(c)(3).","type":"research"}],"applicability":"For patients and caregivers looking for community, education or help navigating care. Inclusion is not a recommendation or a finding that this group is right for your situation.","limitations":"Program details are reported by the group unless noted, as of October 2026. Confirm current programs, eligibility and any costs directly with the group. A community group does not give medical advice.","disclosure":{"type":"none","text":"I have no financial or business relationship with this organization."},"reviewedAt":"2026-10-22","relatedIds":["656030c7-047a-40e9-b47b-14b19f3fd2bd"],"assetIds":["85f92e52-8bde-4630-860b-f05ad886034a","4dd3b10b-dc15-41cb-9468-8259d08cf6eb"],"relatedX":[],"website":"https://www.exon20group.org/","serviceStatus":"available","facts":[{"label":"Who it serves","value":"People with EGFR or HER2 exon 20 insertions in lung cancer or other solid tumors, and their families.","sourceIds":["home"]},{"label":"Cost","value":"As of October 2026, membership is free after an onboarding intake.","sourceIds":["home"]},{"label":"Parent organization","value":"Special initiative of ICAN, International Cancer Advocacy Network, a 501(c)(3) (EIN 86-0818253).","sourceIds":["home","propublica"]},{"label":"Navigation","value":"Biomarker report review, second opinion referrals, trial, expanded access and compassionate use matching.","sourceIds":["home"]}],"id":"47b40593-5355-473b-9161-a6875226feb8","kind":"company","slug":"exon-20-group","revision":"e50dfc71-5eca-48e6-9184-5a9ec4c78a3e","canonicalUrl":"https://kevinwimer.com/companies/exon-20-group/","publishedAt":"2026-10-25T02:18:32.515Z","updatedAt":"2026-10-25T02:18:32.515Z","previewOnly":false,"logoAssetId":"85f92e52-8bde-4630-860b-f05ad886034a","logoBackground":"dark","logoSource":{"pageUrl":"https://www.exon20group.org/","assetUrl":"https://www.exon20group.org/img/logo/exon20group-logo-white.svg","checkedAt":"2026-10-23T03:19:21.396Z"},"shareImageAssetId":"4dd3b10b-dc15-41cb-9468-8259d08cf6eb"}